Baseline characteristics of patients in the brace trial
| Statistic | No Brace Group (N=63) mean (SD) | Brace Group (N=63) mean (SD) |
|---|---|---|
| Age | 56.4 (8.1) | 54.5 (6.7) |
| % Female | 50.8% | 63.5% |
| BMI (kg/m2) | 30.5 (5.1) | 31.4 (6.3) |
| Baseline pain on nominated activity VAS (0–10 cm) | 6.3 (2.1) | 6.8 (2.1) |
| Baseline KOOS pain subscale score (100–0) | 51.1 (18.4) | 48.2 (18.4) |
| Baseline KOOS ADL subscale score (100–0) | 57.0 (19.2) | 52.7 (22.0) |
| Total bone marrow lesion volume (mm3)—all patients | 4460.4 (6322.0) | 5816.5 (7686.9) |
| Patellofemoral bone marrow lesion volume—all patients | 2088.1 (2938.8) | 3039.4 (3974.9) |
| Tibiofemoral bone marrow lesion volume—all patients | 2372.3 (6010.5) | 2777.1 (5338.4) |
| Total bone marrow lesion volume (mm3)—patients with BMLs only | 4606.7 (6373.0) | 6439.7 (7838.9) |
| Patellofemoral bone marrow lesion volume—patients with BMLs only | 2859.9 (3105.4) | 3925.9 (4117.3) |
| Tibiofemoral bone marrow lesion volume—patients with BMLs only | 3933.0 (7364.1) | 4531.1 (6230.6) |
| Bone marrow lesion prevalence (N, %): | – | – |
| Patients with no bone marrow lesions (whole knee) | 2, 3.2% | 6, 9.7% |
| Patients with no patellofemoral bone marrow lesions | 17, 27% | 14, 22.6% |
| Patients with no tibiofemoral bone marrow lesions | 25, 39.7% | 24, 38.7% |
| Total synovitis volume (mm3) | 29 807.5 (14 469.4) | 29 651.5 (13 570.1) |
| Synovitis prevalence (N, %): | – | – |
| Patients with no synovitis (whole knee) | 0, 0% | 0, 0% |
All figures are presented as mean (SD) unless otherwise specified.
ADL, activities of daily living; BMI, body mass index; BML, bone marrow lesion; KOOS, Knee Osteoarthritis Outcome Score; VAS, visual analogue scale.